Young  Kwon net worth and biography

Young Kwon Biography and Net Worth

Director of ADMA Biologics
Dr. Kwon is presently an operating partner at Lightstone Ventures (“LSV”), assisting the LSV biopharmaceutical team with deal sourcing, due diligence, and portfolio management. Prior to LSV, he served as Chief Financial and Business Officer at Momenta Pharmaceuticals, a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, where he most recently led the sale of Momenta to Johnson & Johnson for approximately $6.5 billion in 2020. At Momenta, he led all finance-related and business development initiatives, including those pertaining to the development efforts of M254, Momenta’s hypersialylated IG clinical program. Prior to Momenta, Dr. Kwon was a business development professional at Biogen, driving a variety of transactions.

Dr. Kwon received a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University and a B.S. in Biology from MIT.

What is Young Kwon's net worth?

The estimated net worth of Young Kwon is at least $1.03 million as of August 24th, 2023. Dr. Kwon owns 277,401 shares of ADMA Biologics stock worth more than $1,029,158 as of December 10th. This net worth approximation does not reflect any other investments that Dr. Kwon may own. Learn More about Young Kwon's net worth.

How do I contact Young Kwon?

The corporate mailing address for Dr. Kwon and other ADMA Biologics executives is 465 STATE ROUTE 17, RAMSEY NJ, 07446. ADMA Biologics can also be reached via phone at (201) 478-5552 and via email at [email protected]. Learn More on Young Kwon's contact information.

Has Young Kwon been buying or selling shares of ADMA Biologics?

Young Kwon has not been actively trading shares of ADMA Biologics within the last three months. Most recently, on Thursday, August 24th, Young Kwon bought 25,000 shares of ADMA Biologics stock. The stock was acquired at an average cost of $3.90 per share, with a total value of $97,500.00. Following the completion of the transaction, the director now directly owns 277,401 shares of the company's stock, valued at $1,081,863.90. Learn More on Young Kwon's trading history.

Who are ADMA Biologics' active insiders?

ADMA Biologics' insider roster includes Adam Grossman (CEO), Young Kwon (Director), and Brian Lenz (CFO). Learn More on ADMA Biologics' active insiders.

Are insiders buying or selling shares of ADMA Biologics?

During the last year, ADMA Biologics insiders bought shares 2 times. They purchased a total of 155,000 shares worth more than $579,800.00. During the last year, insiders at the biotechnology company sold shares 4 times. They sold a total of 2,405,351 shares worth more than $9,875,174.54. The most recent insider tranaction occured on August, 30th when Director Jerrold B Grossman bought 130,000 shares worth more than $482,300.00. Insiders at ADMA Biologics own 6.0% of the company. Learn More about insider trades at ADMA Biologics.

Information on this page was last updated on 8/30/2023.

Young Kwon Insider Trading History at ADMA Biologics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2023Buy25,000$3.90$97,500.00277,401View SEC Filing Icon  
10/25/2021Buy100,000$1.00$100,000.00View SEC Filing Icon  
See Full Table

Young Kwon Buying and Selling Activity at ADMA Biologics

This chart shows Young Kwon's buying and selling at ADMA Biologics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ADMA Biologics Company Overview

ADMA Biologics logo
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Read More

Today's Range

Now: $3.71
Low: $3.70
High: $3.77

50 Day Range

MA: $3.57
Low: $3.08
High: $4.03

2 Week Range

Now: $3.71
Low: $2.94
High: $4.65


1,100,202 shs

Average Volume

1,354,915 shs

Market Capitalization

$838.35 million

P/E Ratio


Dividend Yield